Admedus Ltd (ASX:AHZ) has confirmed that it will implement a Coronavirus mitigation strategy to limit the risk of an interruption to the continuity of supply and operations.
The company expects the impacts on operations to be minimal but will monitor the situation closely.
In the meantime, the company continues operating to plan and key projects are progressing as scheduled.
Manufacturing continues[hhmc]
The company is continuing to manufacture product for LeMaitre Vascular Inc (FRA:LHU).
LeMaitres feedback on its CardioCel® and VascuCel® patch sales remains positive with no downturn in customer orders at this stage.
Notably, the first-in-human 15 patient trial of the companys ADAPT® single-piece 3D aortic valve for surgical aortic valve replacement at the Universities Hospital, Leuven (Belgium) remains on track to proceed as scheduled with the first patient expected to undergo surgery by months end.
However, disruption due to COVID-19 demands on hospital resources may delay this into April 2020.
Some disruptions expected[hhmc]
The chief disruption to date is to corporate and medical conferences due to event cancellations and travel restrictions.
The companys advisory board of physicians continues to meRead More – Source
[contf]
[contfnew]
Proactiveinvestors
[contfnewc]
[contfnewc]
